Immune-mediated colitis associated with ocrelizumab: A new safety risk.

Tiffany KimAllen BrinkerDavid CroteauPaul R LeeLaura E BaldassariJessica StevensAlice HughesJuli TomainoArushi deFonsekaTara AltepeterCindy M Kortepeter

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

This case series highlights ocrelizumab induced immune-mediated colitis that can be clinically severe and potentially life-threatening. Based on the findings of this review, the ocrelizumab Prescribing Information was amended to include immune-mediated colitis in the Warnings and Precautions section.

Keyphrases

ulcerative colitis
primary care
drug induced
high glucose
diabetic rats
early onset
healthcare
emergency department
oxidative stress
endothelial cells
health information
sewage sludge